About Daniel Spiegelman
Daniel Spiegelman is a director at vTv Therapeutics.
Form D filings name Daniel Spiegelman as a director at Kyverna Therapeutics.
Daniel Spiegelman reports to the SEC as a director or officer of 14 public companies, including Maze Therapeutics (MAZE), Spruce Biosciences (SPRB) and Kyverna Therapeutics (KYTX).
Daniel Spiegelman first appears on SEC filings in 2006.
Experience
This experience comes from SEC filings. The years are when the filings name Daniel Spiegelman in the role, so the role may have started earlier or lasted longer.
VI
vTv Therapeutics Inc.
Director
2024 – 2026 · Public company (VTVT)
MI
Maze Therapeutics, Inc.
Director
2025 – 2026 · Public company (MAZE)
SI
Spruce Biosciences, Inc.
Director
2020 – 2026 · Public company (SPRB)
MI
Myriad Genetics Inc.
Director
2020 – 2024 · Public company (MYGN)
JC
Jiya Acquisition Corp.
Director
2020 · Public company (JYAC)
BI
Biomarin Pharmaceutical Inc.
EVP, Chief Financial Officer
2012 – 2019 · Public company (BMRN)
CI
Cascadian Therapeutics, Inc.
Director
2008 – 2018 · Public company (CASC)
RI
Relypsa Inc
Director
2014 – 2016 · Public company (RLYP)
AI
Anthera Pharmaceuticals Inc
Director
2010 – 2014 · Public company (ANTH)
AI
Affymax Inc.
Director
2006 – 2012 · Public company (AFFY)
OC
Omeros Corp.
Director
2009 – 2012 · Public company (OMER)
BI
Bio Green Med Solution, Inc.
Director
2006 – 2012 · Public company (BGMS)
CI
CV Therapeutics Inc.
SVP, CFO
2006 – 2009 · Public company (CVTX)
Key Colleagues at Startups
The people Daniel Spiegelman works with at each company, as listed on that company's latest Form D.
Kyverna Therapeutics, Inc. · Form D, Nov 7, 2023
BK
Brian Kotzin
Director
IC
Ian Clark
Director
RJ
Ryan Jones
Chief Financial Officer
KW
Karen Walker
Executive officer
PM
Peter Maag
Executive officer and director
JC
James Chung
Executive officer
BS
Beth Spiegelman
Director
FC
Fred Cohen
Director
SL
Steve Liapis
Director
DB
Dominic Borie
Executive officer